Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).

被引：4
|
作者：
Adib, Elio [1 ]
Jain, Rohit K. [2 ]
Skelton, William Paul [3 ]
Freeman, Dory [1 ]
Curran, Catherine [1 ]
Akl, Elie W. [4 ]
Nassar, Amin [4 ]
Ravi, Praful [1 ]
Mantia, Charlene [1 ]
Merchan, Jaime R. [5 ]
Tan, Winston [6 ]
Plastini, Trisha M. [7 ]
Choueiri, Toni K. [1 ,8 ]
Sonpavde, Guru [9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Lee Moffitt Canc Ctr, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Univ Miami, Miami, FL USA
[6] Mayo Clin Hosp, Jacksonville, FL USA
[7] Univ Penn Hlth Syst, Philadelphia, PA USA
[8] Harvard Med Sch, Boston, MA 02115 USA
[9] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
472
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results
    Funt, Samuel A.
    Grivas, Petros
    Gao, Xin
    Vaena, Daniel A.
    Zhang, Tian
    Milowsky, Matthew I.
    Rao, Mayank
    Liu, Harry
    Tipton, Kimberly
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Randolph, Sophia
    Tsiatis, Athanasios C.
    Jain, Rohit K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] BT8009 monotherapy in enfortumab vedotin (EV)-naive patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
    Reig Torras, O.
    Crouzet, L.
    Necchi, A.
    Baldini, C.
    Lostes Bardaji, M. J.
    Doger de Speville, B.
    Italiano, A.
    Verlingue, L.
    Boni, V.
    Carter, L.
    Duran, I.
    Garmezy, B.
    Galsky, M. D.
    Falchook, G. S.
    DeMars, L.
    Josephs, K.
    Xu, C.
    Bader, J.
    Fontana, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S515 - S516
  • [33] Single-center retrospective analysis of safety and efficacy of dose-reduced enfortumab vedotin (EV) in frail patients with metastatic urothelial carcinoma (mUC)
    Song, Wilbur
    Tao, Yu
    Luo, Jingqin
    Roth, Bruce J.
    Reimers, Melissa Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
    Minato, Akinori
    Furubayashi, Nobuki
    Nagata, Yujiro
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Song, Yoohyun
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Kuroiwa, Kentaro
    Seki, Narihito
    Tomisaki, Ikko
    Harada, Kenichi
    Nakamura, Motonobu
    Fujimoto, Naohiro
    CURRENT ONCOLOGY, 2024, 31 (02) : 862 - 871
  • [35] Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
    Al Hanafy, A. M.
    Fathy, S.
    Eldin, M. Serag
    Holah, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1565 - S1565
  • [36] Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma
    Sethakorn, Nan
    O'Donnell, Peter H.
    BJU INTERNATIONAL, 2016, 118 (05) : 680 - 690
  • [37] Prognostic impact of fibroblast growth factor receptor (FGFR) genomic alterations and outcomes in patients with metastatic urothelial.
    Sevillano, Elena
    Madurga, Rodrigo
    Moreno, Juan Francisco Rodriguez
    Barquin, Arantzazu
    Yague, Monica
    Navarro, Paloma
    Barba, Maria
    Quiralte, Miguel
    Garcia-Donas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin
    Jindal, Tanya
    Zhang, Li
    Deshmukh, Prianka
    Reyes, Kevin
    Chan, Emily
    Kumar, Vipul
    Zhu, Xiaolin
    Maldonado, Edward
    Feng, Stephanie
    Johnson, Michelle
    Angelidakis, Austin
    Kwon, Daniel
    Desai, Arpita
    Borno, Hala T.
    Bose, Rohit
    Wong, Anthony
    Hong, Julian
    Carroll, Peter
    Meng, Maxwell
    Porten, Sima
    Aggarwal, Rahul
    Small, Eric J.
    Fong, Lawrence
    Chou, Jonathan
    Friedlander, Terence
    de Kouchkovsky, Ivan
    Koshkin, Vadim S.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : e394 - e404
  • [39] PATTERN OF EXPRESSION AND MUTATION STATUS OF FGFR2/3 AND NECTIN-4 IN UROTHELIAL CARCINOMA
    Inamoto, Teruo
    Komura, Kazumasa
    Uehara, Hirofumi
    Uchimoto, Taizo
    Saito, Kenkichi
    Tanda, Naoki
    Matsunaga, Tomohisa
    Ichihashi, Atsushi
    Tsutsumi, Takeshi
    Tsujino, Takuya
    Yoshikawa, Yuki
    Takai, Tomoaki
    Minami, Koichiro
    Taniguchi, Shunri
    Ibuki, Naokazu
    Hirano, Hajime
    Nomi, Hayahito
    Azuma, Haruhito
    JOURNAL OF UROLOGY, 2020, 203 : E1008 - E1008
  • [40] Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
    Jindal, Tanya
    Zhu, Xiaolin
    Bose, Rohit
    Kumar, Vipul
    Maldonado, Edward
    Deshmukh, Prianka
    Shipp, Chase
    Feng, Stephanie
    Johnson, Michelle S.
    Angelidakis, Austin
    Kwon, Daniel
    Borno, Hala T.
    de Kouchkovsky, Ivan
    Desai, Arpita
    Aggarwal, Rahul
    Fong, Lawrence
    Small, Eric J.
    Wong, Anthony
    Porten, Sima
    Chou, Jonathan
    Friedlander, Terence
    Koshkin, Vadim S.
    FRONTIERS IN ONCOLOGY, 2023, 13
12345